IPHA Innate Pharma S.A.
$1.48▲ +1.37%
Healthcare
Other
Volume 16.8K
Avg Volume (10D) 13.7K
Key Metrics & Fundamentals
Market Cap
$165.32M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.17 - 2.71
% vs 50 MA
-17.86%
% vs 200 MA
-13.84%
RSI-14
40.9
MACD Histogram
+0.0100
Beta (1Y vs SPY)
1.70
Gross Rev
–
Gross Profit
–
EBITDA
–
COGS
–
Operating Exp
–
Operating Income
–
EBIT
–
Pretax Income
–
Net Income
–
Price & Volume History
Loading chart…
Recent News
Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027
Business Wire · Oct 27, 2026 2:00 AM ET
Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference
Business Wire · Oct 21, 2026 1:00 AM ET
Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update
Business Wire · Oct 20, 2026 1:00 AM ET
Down 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a Turnaround
Zacks · Oct 8, 2026 8:35 AM ET
Down 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA)
Zacks · Oct 5, 2026 8:35 AM ET
Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should Know
Zacks · Sep 23, 2026 12:00 PM ET
Innate Pharma (IPHA) Closes Sobi Deal. Can the New Funding Keep Drug Trials on Track?
Insider Monkey · Sep 22, 2026 8:40 PM ET
Innate Pharma (IPHA) Q2 2026 Earnings Call Transcript
Motley Fool · Sep 17, 2026 11:07 PM ET
Innate Pharma Q2 Earnings Call Highlights
MarketBeat · Sep 17, 2026 9:02 AM ET
Innate Pharma Reports First Half 2026 Business Update and Financial Results
Business Wire · Sep 17, 2026 1:00 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.